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Psoriasis Is Not a Useful Independent 
Risk Factor for Cardiovascular Disease
Robert S. Stern1
Since Gelfand’s 2006 publication, the hypothesis that psoriasis is a risk factor for 
myocardial infarction (MI) and cardiovascular disease (CVD) has drawn substantial 
attention (Gelfand et al., 2006). Makers of biologic therapies for psoriasis, whose 
products cost $15,000 to $25,000 per patient treated per year, are prominent spon-
sors of symposia and publications that have advanced this hypothesis (Strober et al., 
2008; Friedewald et al., 2008). A company-supported clinical trial testing the hypoth-
esis that tumor necrosis factor (TNF) inhibitor therapy of psoriasis may also reduce 
cardiovascular risk is under way (ClinicalTrials.gov, 2007). In this issue, Wakkee et al. 
provide additional evidence that it is unlikely that either psoriasis or severe psoriasis 
is a relevant risk factor for MI. Even if—after accounting for confounding and bias—
psoriasis is significantly associated with CVD risk, psoriasis is unlikely to be a clini-
cally useful independent risk factor for CVD.
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To evaluate the clinical utility of psoriasis 
as a risk factor for cardio vascular disease 
(CVD), I have applied five criteria advo-
cated by the US Preventative Task Force 
for evaluating new risk factors for heart 
disease (Helfand et al., 2009).
1. the risk factor should be easily and 
reliably measured.
Can patients with psoriasis be reliably distin-
guished from those without psoriasis? Even 
when assessed by dermatologists, reliable 
and reproducible diagnostic criteria for mild 
psoriasis are lacking (Rzany et al., 1997). A 
nondermatologist’s diagnosis of psoriasis is 
even less likely to be reliable (i.e., to have 
high sensitivity and specificity).
Most epidemiologic studies that dem-
onstrated an association of severe pso-
riasis and CVD used process measures 
to define severe psoriasis (Gelfand et al., 
2006; Friedewald et al., 2008). Process-
based measures of disease severity are 
particularly vulnerable to bias. Behavioral 
and socioeconomic factors affect both 
the process of care and the likelihood 
an individual will seek care. Therefore, 
process measures are unlikely to reliably 
discriminate between patients who, by 
“objective” clinical criteria, would be 
considered to have severe psoriasis and 
those with less severe disease.
There is no reproducible, or even 
agreed on, clinically or biologically based 
definition of severe psoriasis. The lack of 
a good measure to accurately classify an 
affected person’s severity for purposes of 
CVD risk stratification is further compli-
cated by the variability of an individual’s 
extent and burden of psoriasis over time 
and the fact that external factors may alter 
psoriasis “severity.” Is a single episode of 
extensive psoriasis or use of a systemic 
agent sufficient to classify that patient as 
severe? Does a person who had a flare of 
psoriasis after strep tococcal infection, but 
who otherwise has limited disease, have 
severe psoriasis?
2. It should be an independent predictor of 
major cVD events in persons of intermediate 
risk who have no history of cVD.
Most data suggesting an association 
between psoriasis and CVD have come 
from specialized populations at either 
low or high risk of CVD. The individuals 
studied often lacked clear or complete his-
tories of CVD. The strongest associations 
were observed in groups defined post 
hoc. In Gelfand and colleagues’ JAMA 
study (2006), the only strong assoc iation 
between psoriasis and myocardial infarc-
tion (MI) was for young individuals (a post 
hoc subset analysis) with severe psoriasis 
(process defined). This highest-relative-risk 
group (severe psoriasis in patients younger 
than age 50) had a low baseline risk of MI 
(<1 in 1,000 per year) and comprised only 
1/4,000 of the total population served by 
study practitioners and 3% of those iden-
tified as having psoriasis.
3. When assessed in individuals at 
intermediate risk, the risk factor should 
reclassify a substantial portion as high risk.
The associations of intermediate psoriasis 
with CVD in groups have been weak 
(relative risk <1.5) and often not sig-
nificant (Gelfand et al., 2006; Brauchli 
et al., 2009). The prevalence of psoriasis 
in the general population is relatively low 
(2 to 3%). The prevalence of indiv iduals 
ident ifiable as having severe psoriasis in 
population-based studies is very low. The 
point prevalence of psoriasis involving 
10% of the body surface area is less than 
1 in 5,000 (Stern et al., 2004). Therefore, 
if psoriasis (or severe psoriasis) is utilized 
as an additional risk factor, the CVD risk 
category would change for only a few 
people. Wakkee et al. (2010, this issue) 
found that when traditional risk factors 
are considered, having psoriasis does not 
reclassify MI risk in a substantial number 
of persons.
4. reclassified individuals should be 
managed differently.
At high and increasing frequency, I have 
received “literature” that suggests bio-
logic therapies for psoriasis may lower 
CVD risk (Strober and Young, 2009). In 
addition, a company-sponsored study 
designed to show that etanercept will 
reduce the inflammation associated with 
metabolic syndrome and decrease the 
risk of heart disease in patients with pso-
riasis treated with etanercept is “under 
way” (ClinicalTrials.gov, 2007). Changes 
in C-reactive protein (CRP) appear to be 
the primary end point for this study.
CRP is, at best, a relatively moderate 
predictor of coronary heart disease, with 
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borderline significance (Danesh et al., 
2004; Wilson et al., 2005; Melander et 
al., 2009). Even if tumor necrosis fac-
tor (TNF) blockers lower CRP, it is highly 
speculative that a lower CRP will be 
associated with CVD benefits. A recent 
meta-analysis that assessed this issue 
concluded, “Sufficient evidence that 
reducing CRP levels prevents coronary 
heart disease events is lacking” (Buckley 
et al., 2009).
CRP elevation may be more frequent 
among patients with more extensive psor-
iasis. However, in a company-sponsored 
retrospective analysis, etanercept 
reduced CRP levels in some but not other 
groups of psoriasis patients (Strober et 
al., 2008). Without good evidence that 
lowering CRP levels (or other mediators 
or cytokines that biologic agents might 
decrease) will have a beneficial effect on 
CVD among persons with severe psoria-
sis, claims that therapies that reduce CRP 
level will also lower CVD risk should be 
viewed with skepticism.
One might be more optimistic about 
biologics reducing CVD risk if systemic 
levels (as opposed to skin levels) of a 
biologic’s target, such as TNF-α, were 
substantially elevated in persons with 
psoriasis and higher systemic levels of 
the target were independent predictors 
of CVD risk. Robust evidence that sys-
temic levels of TNF-α (or other targets of 
biologics) are substantially elevated in 
patients with psoriasis, or that systemic 
levels of these targets are highly associ-
ated with psoriasis severity, is lacking. 
Evidence that higher systemic levels of 
TNF-α or other targets of biologics are 
strong independent predictors of coro-
nary heart disease or CVD risk is also 
lacking (Jefferis et al., 2009). Therefore, 
expecting that an agent with a specific 
target such as TNF-α or IL-12 (neither is a 
well-established risk factor for CVD) will 
reduce CVD is at best wishful thinking.
The nonsteroidal anti-inflammatory 
drug experience with CRP and CVD 
risk provides a cautionary tale. One 
year before the withdrawal of rofe-
coxib because of increased CV risk, a 
study demonstrated that Cox-2 inhibi-
tors lowered CRP levels and posited that 
Cox-2 inhibitors might reduce CVD risk 
(Chenevard et al., 2003). Clinical trials 
proved this hypothesis to be very wrong 
(Waxman, 2005).
The homocysteine story provides further 
caution about the validity of the hypoth-
esis that lowering levels of a substance 
associated with CVD will lower CVD 
risk. Homocysteine is an established risk 
factor for cardio vascular disease. Vitamin 
B supplementation reduces homo-
cysteine levels. Two random ized placebo 
control trials, enrolling nearly 7,000 
patients, showed that vitamin B supple-
mentation reduces homocysteine levels 
(Bonaa et al., 2006; Ebbing et al., 2008). 
However, vitamin B therapy had no effect 
on the risk of mortality or cardiovascular 
events. The results of one trial suggested 
a harmful effect of vitamin B supplemen-
tation (Bonaa et al., 2006). In patients 
with psoriatic arthritis, a TNF-α inhibitor 
lowered homocysteine levels but raised 
triglyceride and apolipoprotein B levels, 
which could increase CVD risk (Sattar 
et al., 2007). Previously, vitamin B had 
been considered a reasonably innoc uous 
treatment. The same cannot be said for 
biologic therapies.
5. If two or more risk factors provide 
similar prognostic information, then con-
venience, cost, and safety may be impor-
tant in choosing among them.
Neither psoriasis nor severe psoriasis 
is likely to provide nearly as precise or 
important prognostic information as 
traditional risk factors for CVD such as 
blood pressure, body mass index (obe-
sity), depression, diabetes, smoking, lipid 
levels, and lack of exercise.
A number of these established CVD 
risk factors may be more frequent in 
psoriasis patients (particularly those with 
severe disease) than in the general pop-
ulation (Naldi et al., 2005). Therefore, 
physicians caring for psoriasis patients 
should assess these established risk 
factors for cardio vascular disease. If 
risk factors are present, the clinician 
should help in their optimal manage-
ment. Improving a patient’s psoriasis is 
likely to help depression and encour-
age changes in lifestyle such as smoking 
cessation, weight loss, and increased 
exercise, which reduce CVD risk. The 
consideration of CVD risk reduction as 
a potential benefit of biologic therapy 
per se is at best premature, not evidence 
based, and potentially wrong-headed. 
Providing good dermatologic care 
includes being aware of a patient’s CVD 
risk factors and facilitating preventive 
care and lifestyle changes. Believing 
that psoriasis or severe psoriasis is a 
clinically useful independent risk factor 
for CVD, or that targeted therapies for 
psoriasis will directly reduce CVD risk, 
is at best unproven and most likely not 
the case.
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Psoriasis and Cardiovascular Risk: 
Strength in Numbers
Joel M. Gelfand1,2, Rahat S. Azfar1,2,3 and Nehal N. Mehta2,4
In this issue, Wakkee and colleagues report a self-described exploratory cohort 
study and conclude that psoriasis may not be an independent risk factor for 
ische mic heart disease (IHD) hospitalization and that there is only a slight and 
borderline increased risk of ischemic heart disease among psoriasis patients. 
This negative result should be interpreted in light of the study’s limitations, 
the complex relationship among levels of psoriasis severity, patient age, and 
cardiovascular (CV) risk, and the context of the rapidly growing literature.
Journal of Investigative Dermatology (2010) 130, 919–922. doi:10.1038/jid.2010.12
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When interpreting a negative study, 
two basic principles must be evalu-
ated. First, are the data on exposure, 
outcome, and covariables (such as con-
founders) valid? By valid, we mean does 
the study measure what it intends to 
measure? Database studies, especially 
those using administrative data in which 
the primary purpose is for payment, 
are prone to error in that the electronic 
code entered by a health care provider 
or administrator may not reflect the 
true clinical state of the patient (Strom, 
2005). Such errors (called misclassi-
fication bias) may mask true associa-
tions and yield false-negative results. 
Multiple approaches are necessary to 
validate a database code, including 
medical-record review to determine the 
predictive value of an electronic code 
to reflect the true clinical state (Rawson 
and D’Arcy, 1998). For example, in the 
General Practice Research Database 
(GPRD), the positive predictive value of 
a psoriasis code was about 90%, based 
on a medical record review conducted 
by general practitioners 3–4 years after 
the entry of diagnostic codes (Neimann 
et al., 2006). Similarly, other investiga-
tors have shown in the GPRD that the 
positive predictive value of an acute 
myocardial infarction (MI) code is 90% 
based on a review of medical-record 
data that included factors such as diag-
nostic electrocardiogram changes, 
chest pain presentations, and cardiac 
enzymes (Meier et al., 1998; Hammad 
et al., 2008).
Wakkee and colleagues (2010, 
this issue) do not present data on the 
positive predictive value of their coding 
algorithm to measure the exposure of 
interest (psoriasis) or the outcome of 
interest (hospitalizations for ischemic 
heart disease (IHD)) using the gold 
standard of medical-record review. 
Thus, one cannot exclude misclas-
sification bias as a source of error 
that explains their negative results. 
Furthermore, Wakkee et al. did not 
report the results of their multivariable 
model, so we are unable to determine 
whether their approach was able to con-
firm the expected relationships between 
cardiovascular (CV) risk factors and 
hospitalization for acute IHD (von Elm 
et al., 2007).
The second basic principle is statisti-
cal error. The key question is whether a 
study has the statistical power to detect 
a clinically meaningful association, 
if one truly exists. Wakkee et al. show 
in Table 2 of their article that the haz-
ard ratios for acute IHD hospitalization 
(primary end point) and acute myocar-
dial infarction (secondary end point), 
adjusted for prior use of antihyper-
tensive, antidiabetic, and lipid-lowering 
